Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
motavizumab + palivizumab
- Development stage
- Preclinical
- Lead developer
- MedImmune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
Motavizumab + palivizumab is a combination of two monoclonal antibodies developed for prophylaxis against *respiratory syncytial virus (RSV)* infection in high-risk pediatric patients. Both antibodies target the highly conserved neutralizing epitope on the RSV fusion (F) protein, inhibiting virus-mediated cell-to-cell and virus-to-cell fusion, leading to decreased viral replication and spread. Palivizumab is established for the prevention of serious RSV-related respiratory disease in high-risk infants and young children. Motavizumab is an affinity-optimized derivative of palivizumab, designed to provide enhanced potency and protection, showing improved binding affinity and microneutralization activity over palivizumab. The combination is not an approved clinical product but may be considered for comparative or combinatorial research purposes[1][3][4].
- Brand names
- Synagis
- Other names
- palivizumab systemic
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on motavizumab + palivizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on motavizumab + palivizumab.